OBJECTIVE -Endothelin (ET)-1 is a vasoconstrictor and proinflammatory peptide that may inhibit glucose uptake. The objective of the study was to investigate if ET (selective ET A and dual ET A ϩET B ) receptor blockade improves insulin sensitivity in patients with insulin resistance and coronary artery disease.
I
nsulin resistance is a key component of the metabolic syndrome and is associated with increased cardiovascular risk (1) . Impairment of endothelial function, characterized by reduced bioactivity of nitric oxide (NO), is an early finding in patients with insulin resistance (2) and type 2 diabetes (3). Besides the negative effects on NO availability, insulinresistant states such as type 2 diabetes (4), obesity (5) , essential hypertension (6) , and coronary artery disease (7) are associated with elevated plasma levels of the endothelium-derived vasoconstrictor and proinflammatory peptide endothelin (ET)-1 (8, 9) . Furthermore, insulin may directly stimulate the secretion of ET-1 from endothelial cells (8) .
The vascular responses to ET-1 are mediated via two receptor subtypes: ET A and ET B receptors (10, 11) . Both types of receptors are located on vascular smooth muscle cells and mediate vasoconstriction. The ET B receptor is also located on endothelial cells and mediates vasodilatation by stimulating release of NO and prostacyclin. Early reports show that ET-1 interferes with glucose metabolism as indicated by a drop in splanchnic glucose production and peripheral glucose utilization during ET-1 infusion in healthy subjects (12) . Ferri et al. (4) demonstrated a negative correlation between total glucose uptake and circulating ET-1 levels in non-insulin-dependent diabetes. The notion that ET-1 modulates insulin sensitivity was supported by the demonstration that ET-1 reduces insulin sensitivity in healthy volunteers (13) . Furthermore, the ET-1 precursor, big ET-1, reduces insulin sensitivity via an action mediated by the ET A receptor in healthy subjects (14) . However, no study has investigated whether endogenous ET-1 contributes to reduced insulin sensitivity in patients with insulin resistance. The present study was therefore designed to investigate the impact of ET-1 receptor blockade on insulin sensitivity in patients with insulin resistance and coronary artery disease. Since ET B receptors on vascular smooth muscle have been shown to be upregulated in atherosclerosis (15) and dual ET A ϩET B receptor blockade (but not selective ET A receptor blockade) improves endothelial function in subjects with insulin resistance (16), we compared the effects of selective ET A and dual ET A ϩET B receptor antagonism on insulin sensitivity.
RESEARCH DESIGN AND
METHODS -Seven patients (aged 58 Ϯ 2 years, BMI 31.7 Ϯ 2.6 kg/m 2 ) with a previous history of impaired glucose tolerance and coronary artery disease were recruited. Impaired glucose tolerance was defined as fasting blood glucose Ͻ6.1 mmol/l and a blood glucose Ն7.8 mmol/l 2 h after an oral glucose loading (75 g).
•
Patients were classified as having diabetes if fasting blood glucose was Ն6.1 mmol/l (on at least on two occasions) or blood glucose concentration was Ն11.1 mmol/l 2 h after an oral glucose loading. Based on these criteria, five patients were classified as having diabetes and two as having impaired glucose tolerance. Coronary artery disease was defined as a history of previous myocardial infarction or significant coronary stenosis verified by coronary angiography. The patients were taking aspirin (n ϭ 7), statins (n ϭ 6), fibrates (n ϭ 1), ACE inhibitors (n ϭ 5), ␤-blockers (n ϭ 7), and oral antidiabetic agents (n ϭ 5). Average total, LDL, and HDL cholesterol levels were 4.0 Ϯ 0.3, 2.3 Ϯ 0.3, and 0.9 Ϯ 0.1 mmol/l, respectively. Average serum creatinine was 87 Ϯ 5 mol/l. The subjects were informed of the nature, purpose, and possible risk involved in the study before giving informed consent. The investigation was carried out in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Karolinska Institute.
The study consisted of three different hyperinsulinemic-euglycemic clamp protocols: 1) a control clamp with saline infusion, 2) a clamp with infusion of the ET A receptor antagonist BQ123, and 3) a clamp with a combined infusion of BQ123 and the ET B receptor antagonist BQ788. There was at least 1 week between the clamp studies. There were no dropouts. The investigations were performed in random order, and the patients were unaware of the order of the clamps and thus blinded to the treatments. On the study day, the patient arrived in the laboratory after an overnight fast. All medication was withheld on the study day. Two thin catheters were percutaneously inserted into one antecubital vein of each arm for infusions. The receptor antagonists, saline, cardiogreen, and paminohippurate (PAH) were given in one arm, while glucose and insulin were infused in the contra-lateral arm. Another catheter was introduced into the brachial artery for sampling of blood and measurement of systemic arterial blood pressure. Heart rate and mean arterial blood pressure (MAP) were continuously monitored and recorded every 20 min throughout the studies. Splanchnic blood flow (SBF) and renal blood flow (RBF) were determined by the constant infusions of cardiogreen, PAH, and the hematocrit, as previously described (12) . In a previous study, hepatic and renal vein catheters were introduced to ascertain that fractional uptake, F (equal to the arteriovenous difference divided by the arterial concentration), of cardiogreen and PAH were not influenced by the infusion of the ET-1 blockers (17) or the clamp procedure (14) . As there was no change in the F values, a constant F value of 0.8 for cardiogreen and 0.9 for PAH was used in the present study.
Insulin, dissolved in 0.9% saline and blood, was infused at a rate corresponding to 804 mU/m 2 body surface area during the first 8 min, followed by 40 mU/m 2 per min for 112 min. Fasting blood glucose level was maintained by adjusting the infusion rate of a 20% glucose solution. Arterial blood samples were taken every 5 min for determination of blood glucose. Arterial samples for plasma insulin, cardiogreen, PAH, and hematocrit were collected at 60, 80, 100, and 120 min of the clamp procedure.
In the control clamp, an infusion of saline was started at 60 min into the clamp and was maintained for 15 min. In the BQ123 clamp, the ET A receptor antagonist BQ123 was infused at a rate of 5 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 . In the combined BQ123ϩBQ788 clamp, the ET B receptor antagonist BQ788 was infused at a rate of 4 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 together with BQ123 (5 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 ). The infusions of the antagonists started 60 min into the clamp and were maintained for 15 min. The doses of BQ123 and BQ788 were based on previous studies demonstrating effective hemodynamic responses and antagonism of vascular effects evoked by ET-1 (17) (18) (19) (20) .
Glucose was analyzed in whole blood according to the glucose dehydrogenase method by using a HemoCue B glucose photometer (HemoCue, Ä ngelholm, Sweden) with a precision corresponding to an SD Ϯ0.3 mmol/l. Plasma insulin was analyzed by radioimmunoassay (12) . The hematocrit was analyzed with a microcapillary hematocrit centrifuge and corrected for trapped plasma. Drugs BQ123 (Clinalfa, Läufelfingen, Switzerland) and BQ788 (Neosystem, Strasbourg, France) were dissolved in sterile 0.9% NaCl, which was sterile filtered through a Millipore filter and stored frozen at Ϫ80°C thereafter. On the day of the experiments, all substances were diluted to the proper concentrations in sterile 0.9% NaCl. Insulin (Actrapid, 100 IE/ml; Novo Nordisk, Bagsvaerd, Denmark) was dissolved in 0.9% saline and blood.
Calculations and statistics
The total-body glucose uptake (M; mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was calculated during three 20-min sampling periods from 60 to 120 min during the clamp (i.e., 60 -80, 80 -100, and 100 -120 min). This means that the first sampling was made during ET receptor blockade on the occasions when antagonists were administered. The M value was then corrected for the mean of the two plasma insulin values obtained during each period to calculate the M/I value, which represents a measure of insulin sensitivity. Splanchnic and renal vascular resistance were calculated as MAP divided by SBF or RBF, respectively, and measured 60 min into the clamp, i.e., before administration of the antagonists (baseline), and thereafter every 20 min. A two-way ANOVA with repeated measures on two factors was used to analyze the data. The factors were clamp (three levels) and time (three to four levels). The interaction in the ANOVA refers to the statistical test of whether the effect of one factor, as measured by differences in the response averages, is different for different levels of the other factor. In the case of significant interaction, post hoc interaction tests were performed between each pair of the clamp conditions across the time intervals. Due to positively skewed distribution, the data for M/I were log transformed. Simple effects tests were also performed, i.e., effects of one factor holding the other factor fixed. For these tests, Fischer's protected least significant difference was performed. Data are presented as means Ϯ SE.
RESULTS

Hemodynamic effects
There was no change in heart rate in either group during the clamps, and there were no differences in heart rate between the clamps. There was no difference in MAP between the groups at 60 min, i.e., before administration of antagonists. However, MAP differed between the three clamps (interaction, clamp ϫ time P Ͻ 0.001). When compared with the control clamp, MAP was reduced following administration of BQ123 (clamp ϫ time P Ͻ 0.01) and following administration of BQ123ϩ BQ788 (clamp ϫ time P Ͻ 0.05) ( Table  1) .
RBF at 60 min did not differ between the clamps, and it did not change in the control or BQ123 clamps. In contrast, RBF increased by 24% (P Ͻ 0.01) following administration of BQ123ϩBQ788
Endothelin blockade improves insulin sensitivity (Fig. 1A) . RBF was significantly higher in the BQ123ϩBQ788 clamp compared with the control clamp (P Ͻ 0.01, interaction clamp ϫ time P Ͻ 0.05) and the BQ123 clamp (P Ͻ 0.001). RBF did not differ between the control and the BQ123 clamps. There was no difference in SBF between the three clamps (Fig. 1B ).
There were significant differences in renal vascular resistance between the clamp protocols (P Ͻ 0.05, clamp ϫ time P Ͻ 0.01) (Fig. 1C) . Renal vascular resis- tance was significantly lower in the BQ123ϩBQ788 clamp than in the control clamp (P Ͻ 0.05, clamp ϫ time P Ͻ 0.05). Furthermore, renal vascular resistance was lower in the BQ123ϩBQ788 clamp than in the BQ123 clamp (P Ͻ 0.05). There were no significant differences in splanchnic vascular resistance between the clamp protocols (Fig. 1D ).
Effect on glucose and insulin
Arterial glucose values remained unchanged and did not differ between the clamps. There were no differences in arterial insulin levels between the three clamp protocols (Table 1) . Glucose uptake and insulin sensitivity were determined during saline infusion in the control clamp and following antagonist administration in the BQ clamps. There were significant (P Ͻ 0.05) differences in total-body glucose uptake, M values, between the three clamp protocols (Fig. 2A) . The M value was significantly higher in the in the BQ123ϩBQ788 clamp than in the control clamp and in comparison with the BQ123 clamp (P Ͻ 0.05). There was no difference in M value between the control and the BQ123 clamps. There were differences in insulin sensitivity, expressed as M/I values, between the three clamps (P Ͻ 0.02). The M/I value was significantly higher in the BQ123ϩBQ788 clamp than in the control clamp (P Ͻ 0.01) and the BQ123 clamp (P Ͻ 0.05). The M/I value tended to be higher already at the first measurement during dual receptor blockade with BQ123ϩBQ788, and it became significantly higher in comparison with the other groups at measurements two and three (Fig. 2B) . There was no difference between the control clamp and the BQ123 clamp.
CONCLUSIONS -The main finding of the present study is that total-body glucose uptake (M) and insulin sensitivity (M/I) were acutely increased during dual ET A ϩET B receptor blockade in obese patients with insulin resistance and coronary artery disease. On the other hand, no difference in M or M/I values were observed following selective ET A receptor blockade. These observations indicate that ET-1 contributes to insulin resistance and that the ET B receptor plays an important role.
Previous studies (2) have demonstrated that plasma levels of ET-1 are elevated in patients with insulin resistance and/or type 2 diabetes. Furthermore, a negative correlation between total glucose uptake and circulating ET-1 levels was found in diabetic patients (4) . In that study, no correction was done for the insulin levels, and the correlation between ET-1 and insulin sensitivity could not be elucidated. Other studies show that administration of exogenous ET-1 reduces insulin sensitivity in healthy humans (13) and in experimental animals (21) . However, the role of endogenous ET-1 in the regulation of insulin sensitivity in cardiovascular disease is still incompletely understood. Based on these previous observations, we hypothesized that endogenous ET-1 is involved in the regulation of glucose uptake by insulin in patients with insulin resistance and coronary artery disease. To our knowledge, the present study is the first to demonstrate that dual ET A ϩET B receptor blockade acutely increased the M and the M/I values in this group of patients, clearly supporting our hypothesis.
The effect on insulin sensitivity was investigated using both selective ET A and dual ET A ϩET B receptor blockade. Administration of the ET B receptor antagonist alone was not tested, since selective ET B receptor blockade in the absence of ET A receptor blockade may exert adverse hemodynamic effects in patients with heart failure (18) . It is often assumed that most of the pathophysiological effects of ET-1 are mediated via stimulation of the ET A receptor. In vitro studies have shown that ET-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes (22) and isolated skeletal muscle strips (21) mainly through the ET A receptor. Furthermore, chronic selective ET A receptor antagonism improves insulin sensitivity and reduces hyperinsulinemia in animal models (23) . We have shown that ET A receptor blockade improves, while selective ET B receptor blockade impairs, insulin sensitivity during infusion of the ET-1 precursor big ET-1 in healthy humans (14) . In the present study, insulin sensitivity improved only after dual ET A ϩET B receptor blockade but not following selective ET A receptor blockade, indicating that the ET B receptor plays a different role in health and disease. It has previously been demonstrated that the expression of smooth muscle cell ET B receptors that mediate vasoconstriction are increased in atherosclerotic human arteries (15) . The expression of ET B receptors is also increased in mice overexpressing ET-1 (24) , suggesting that there may be a change in balance between ET A and ET B receptors in states of enhanced expression of ET-1. The increased expression of ET B receptors has functional consequences, as dual ET A ϩET B receptor blockade results in more pronounced vasodilatation than selective ET A receptor blockade in the forearm of patients with atherosclerosis (25) , as well as in the renal vascular bed of the present study. Furthermore, dual ET A ϩET B receptor blockade but not selective ET A improves endotheliumdependent vasodilatation in clinically healthy subjects with insulin resistance (16) . Collectively, these observations indicate that dual ET A ϩET B receptor blockade may result in more favorable effects than selective ET A in certain pathophysiological situations. The present data are in accordance with this notion and suggest that dual ET A ϩET B receptor blockade may be preferred over selective ET A receptor blockade in order to improve insulin sensitivity in patients with insulin resistance and coronary artery disease.
The changes in hemodynamic parameters support a role for ET-1 in the regulation of vascular tone. Renal vascular resistance but not splanchnic vascular resistance was reduced by dual receptor blockade, suggesting regional differences regarding the influence of ET-1 on vascular tone in this patient group. The more pronounced effect of dual ET A ϩET B receptor blockade, compared with selective ET A receptor blockade, on renal hemodynamics is in agreement with the effect on M and M/I values. The finding is also in agreement with observations in the forearm of patients with atherosclerosis (25) and indicates importance of ET B receptors contributing to vasoconstrictor tone in cardiovascular disease. However, the results contrast those obtained in patients with chronic renal failure and hypertension (19) . Selective ET A receptor blockade, but not dual ET A ϩET B receptor blockade, increased RBF and reduced renal vascular resistance. Important differences between these studies are that patients in our study had normal renal function, based on serum creatinine levels, and normal blood pressure. Further studies are needed to evaluate the hemodynamic effects of selective ET A receptor blockade versus dual ET A ϩET B receptor blockade in patients with cardiovascular disease.
The mechanism behind the effect of ET-1 on insulin sensitivity is not yet fully understood. Previous studies on healthy humans and on isolated skeletal muscle strips suggest that this effect is independent of a reduction in skeletal muscle blood flow (21) . Instead, the results imply a direct influence of ET-1 on insulinstimulated glucose transport. Accordingly, ET-1 decreases the expression of insulin receptor substrate-1 and its activation of phosphatidylinositol 3-kinase pathway and insulin-stimulated Akt phosphorylation in skeletal muscle vascular smooth muscle cells (21, 26) . Furthermore, a recent study (27) suggests that ET-1 impairs glucose transporter GLUT4 trafficking via interference with phosphatidylinositol 4,5-bisphosphateregulated cytoskeletal events. These observations suggest that ET receptor blockade may result in increased insulin sensitivity via effects on insulin signaling. However, effects related to increased regional blood flow and bioavailability of insulin by ET receptor blockade cannot be ruled out.
A limitation of the present study is that only the acute effect of ET receptor blockade on insulin resistance was investigated in a limited study group. No information is available regarding the longterm effects of dual ET A ϩET B receptor blockade on insulin sensitivity. Furthermore, it cannot be ruled out that a small significant effect in insulin sensitivity by selective ET A receptor blockade may be detected in larger study groups. Based on the present findings, studies using orally available ET receptor antagonists in larger patient groups are warranted to further establish the effect on insulin sensitivity. Nevertheless, the present study was adequately sized to detect a significant effect of dual ET A ϩET B receptor blockade in comparison with the control group and selective ET A receptor blockade. Another limitation is that only one dose of each antagonist was tested. Both protocols using antagonists reduced MAP, demonstrating pharmacological effects. Furthermore, comparable doses have previously been demonstrated to exert hemodynamic effects in patients with heart failure (18) and to antagonize the vasoconstrictor effect of exogenous ET-1 in healthy humans (14, 17, 20) , suggesting efficient doses of both antagonists. It is difficult to speculate whether baseline medication may have influenced insulin sensitivity. However, baseline medication was unchanged during the study, suggesting that any influence on insulin sensitivity was similar on all occasions. In addition, administration of an ACE inhibitor does not attenuate the positive effect of ET receptor blockade on endothelial function in patients with atherosclerosis (28) .
In conclusion, the present study demonstrates that dual ET A ϩET B receptor blockade acutely enhances insulin sensitivity in patients with insulin resistance and coronary artery disease. The data support that ET-1 is involved in the development of insulin resistance and that its negative effect is antagonized by dual ET A ϩET B receptor blockade.
